• iRhom2 Links Odor Signaling to OR Adaptation

  2026-08-28

  Azzopardi and colleagues identify iRhom2 as a distinctive regulator in mouse olfactory sensory neurons, connecting odorant receptor signaling with activity-dependent transcriptional adaptation. Their combination of knockout genetics, transcriptomics, spatial validation, and receptor activation experiments supports an iRhom2–ADAM17 feedback model while also highlighting important limits on causal interpretation.

• 5-Aminolevulinic Acid HCl and Heme Biology

  2026-08-28

  Heme metabolism is emerging as a mechanistic bridge between pathogen virulence, innate immune evasion, and oncology workflows. This article explains how 5-Aminolevulinic acid HCl can help translational researchers interrogate that pathway while maintaining appropriate boundaries between evidence, hypothesis, and application.

• Romidepsin: From HDAC2 to PARP Sensitivity

  2026-08-27

  Romidepsin (FK228) is emerging as more than a chromatin-active compound. New HCC evidence links HDAC2-mediated SmD2 deacetylation to spliceosome control, DNA-repair capacity, and sensitivity to PARP inhibition, creating a biomarker-led framework for translational research.

• AP20187 for Conditional Macrophage Assays

  2026-08-27

  AP20187 provides ligand-controlled fusion protein dimerization for testing causal immune pathways in engineered cell systems. Applied to chronic intermittent hypoxia research, it can complement macrophage, nociceptor, and reporter assays while preserving a clear distinction between validated platform performance and exploratory disease-model translation.

• ML216 BLM Helicase Inhibitor: Assay Workflows

  2026-08-26

  ML216 enables controlled interrogation of BLM-dependent DNA repair, from purified-helicase assays to genotype-matched cell proliferation and sister chromatid exchange studies. This guide connects biochemical potency with practical cancer-research workflows while distinguishing BLM-focused experiments from the WRN mechanism examined in the reference study.

• Filipin III for Reliable Membrane Cholesterol Assays

  2026-08-26

  This scenario-based guide explains how Filipin III, SKU B6034, can strengthen cholesterol detection in membranes alongside cell viability, proliferation, and cytotoxicity assays. It covers assay design, sample compatibility, handling, interpretation, and practical supplier selection without treating filipin fluorescence as a standalone measure of total cellular cholesterol.

• ABT-199 (Venetoclax) Workflow for Apoptosis Research

  2026-08-25

  Build more interpretable apoptosis and viability experiments with ABT-199, a highly selective BCL-2 probe for hematologic malignancy models. This workflow connects dose design, mitochondrial pathway readouts, and combination testing to practical troubleshooting insights from DLBCL research.

• VX-765: Translational Control of Pyroptosis

  2026-08-25

  A mechanistic and strategic guide to using VX-765 and its active metabolite VRT-043198 to distinguish caspase-1-driven cytokine maturation from broader inflammatory signaling and to strengthen translational pyroptosis studies.

• Cyclosporin A: Assays, Workflows, and Optimization

  2026-08-24

  Cyclosporin A enables controlled interrogation of calcineurin–NF-AT signaling, T-cell activation, and cyclophilin-dependent mitochondrial responses. This practical guide separates pharmacologic effects from genetic background, with executable assay parameters and troubleshooting strategies for reproducible immunology and cell biology workflows.

• Pseudo-UTP: A Strategic Lever for Better RNA

  2026-08-24

  A mechanistic and translational guide to using Pseudo-UTP as a design variable in RNA synthesis, mRNA vaccine development, and gene therapy research.

• Phosbind Acrylamide for Phosphorylation Analysis

  2026-08-23

  Phosbind Acrylamide adds a practical, antibody-independent layer to phosphorylation studies by converting phosphate-dependent binding into an SDS-PAGE mobility shift. It is especially useful for mapping treatment-responsive signaling changes, validating kinase or phosphatase activity, and testing phosphorylation hypotheses alongside apoptosis and phase-separation assays.

• TAI-1: From RB1 Organoids to Mitotic Assays

  2026-08-22

  TAI-1 is a potent Hec1 inhibitor whose mitotic mechanism can be studied in more informative, genotype-aware cancer models. This article connects RB1-deficient retinal organoid findings with practical assay design while distinguishing established evidence from testable hypotheses.

• Lisinopril Dihydrate: ACE Inhibitor Research Guide

  2026-08-22

  Lisinopril dihydrate is a water-soluble, long-acting ACE inhibitor used to modulate renin–angiotensin signaling in hypertension research and related cardiovascular and renal models. Its catalog-reported IC50 is 4.7 nM, while formulation, storage, and assay-specific exposure must be controlled independently.

• BCL9–β-Catenin Inhibition Restores PD-1 Response

  2026-08-21

  Feng et al. developed hydrocarbon-stapled peptides that disrupt the β-catenin–BCL9 interaction, suppress oncogenic Wnt transcription, and remodel the tumor immune microenvironment. In preclinical models, the lead peptide reduced regulatory T cells, increased dendritic-cell and cytotoxic T-cell activity, and sensitized tumors to PD-1 blockade, supporting a targeted strategy for overcoming immune checkpoint resistance.

• Arsenic, BBB Disruption, and MMP-2/MMP-9 in Mice

  2026-08-20

  The reference study links sodium arsenite exposure to cognitive impairment through MMP-2/MMP-9-associated blood–brain barrier disruption and hippocampal neuronal apoptosis. Its doxycycline intervention provides pharmacological evidence that preserving barrier integrity can mitigate arsenic-related behavioral and tissue injury, while also highlighting the limits of inferring causality from a single inhibitor.

3569 records 1/238 page Next 12345 下5页 Last page